Crinetics Pharmaceuticals Doses First Patient in Phase 1/2 Trial of CRN09682 for Neuroendocrine Tumors
Crinetics Pharmaceuticals has dosed the first patient in its Phase 1/2 trial of CRN09682 for treating SST2-positive neuroendocrine tumors. The BRAVESST2 trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, enrolling up to 150 participants. This trial marks a significant step in Crinetics' drug development efforts.
Crinetics Pharmaceuticals Inc. has announced the dosing of the first patient in its Phase 1⁄2 clinical trial evaluating CRN09682 for the treatment of metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate (NDC) platform, designed to target SST2-expressing tumor cells and deliver a cytotoxic payload directly within the tumor. The BRAVESST2 trial is a first-in-human, open-label, dose-escalation study with a planned dose expansion phase to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682. Up to 150 participants are expected to be enrolled. The results of the study have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595540-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
